Evaluating a screening test often requires estimation of test sensitiv
ity and specificity with appropriately narrow confidence intervals and
at least cost. If the major cost is the reference (''gold'') standard
, savings arise from reducing the large number of test negatives that
are verified by the reference standard. On the basis of the formulae o
f Begg and Greenes (Biometrics 1983;39:207-15), the authors determine
the optimal sampling strategy for test positives and test negatives to
minimize the total sample size that needs to be verified for a given
confidence interval width for sensitivity. Unless sensitivity is very
high, verifying more test positives and fewer test negatives than woul
d occur with equal sampling fractions is appropriate. For example, if
the sensitivity is 0.7 and the specificity is 0.99, the optimal sampli
ng strategy is for 6.2% of those verified to be test positives, compar
ed with 1.7% in the case of equal sampling fractions. At a disease pre
valence of 0.01, the 3.3-fold increase in test positives results in a
saving of about 15% in the test negatives and 11% in the total verifie
d sample size. Overall, savings are about 50% for a sensitivity of 0.3
, but are negligible when sensitivity is greater than 0.8. Optimal sam
pling strategies for sensitivity do not materially alter confidence in
tervals for specificity. Figures are presented from which readers can
easily obtain the optimal sampling strategy given an estimate of speci
ficity, approximated by the proportion of screenees who are test negat
ive, and the range of likely sensitivity.